Imaging Experts Refine Cancer Staging Approaches
Specialists at CHILI 9.0 weighed how PET, MRI and diagnostic CT each contribute to cancer staging and treatment planning.
Updated on Nov. 13, 2026 in Cancer

Experts at the CHILI 9.0 session discussed how PET, MRI and diagnostic CT contribute to cancer staging and treatment planning. Low-dose CT mainly supports attenuation correction and anatomical localization, while diagnostic CT with contrast can reveal lesions with little radiotracer uptake.
Why it matters
Choosing the right imaging approach is essential to detecting cancer accurately and avoiding unnecessary examinations. Diagnostic CT adds radiation exposure, contrast-related risks, higher costs and greater workflow demands, so its use requires weighing benefits against these trade-offs.
Joint EANM and SNMMI guidelines recommend FDG PET/CT as an option for baseline staging from stage IIB onward in invasive breast cancer of no special type, but not routinely in stage I. FDG PET/CT tracer uptake can be relatively low in certain low-grade and lobular breast cancers, and the comparative value of modalities in each setting remains an open question.
The players
LMU University Hospital
LMU University Hospital is a major academic medical center in Munich, Germany, affiliated with Ludwig Maximilian University of Munich.
Medical University of Vienna
The Medical University of Vienna is one of Europe's leading medical schools and teaching hospitals, based in Vienna, Austria.
Danube Private University
Danube Private University is a private academic institution based in Krems, Austria, with a focus on health and medical education.
The details
Speakers from LMU University Hospital in Munich, Danube Private University in Krems and the Medical University of Vienna addressed how diagnostic CT can clarify ambiguous PET findings and show anatomical details that influence staging. In prostate cancer, PSMA PET and multiparametric MRI can both detect suspicious disease in the same patient but identify lesions in different locations, and targeted FES PET and HER2-targeted PET can reveal receptor expression differences across metastatic lesions.
Timeline
November 12, 2026: CHILI 9.0 session on precision oncology imaging reported.
Health Landscape
The session's discussion builds on the joint EANM and SNMMI guidelines that set FDG PET/CT as an option for baseline staging from stage IIB in invasive breast cancer of no special type. It also reflects the shift toward targeted tracers such as PSMA PET and FES PET, which are being compared against established imaging workflows.
Patients being staged for cancer may encounter different imaging options depending on tumor type and stage, which can affect how quickly a diagnosis is confirmed. Asking a clinician why a particular scan is recommended can help clarify the trade-offs in radiation, cost and accuracy.
The takeaway
Imaging choices in cancer care depend on tumor type, stage and the specific clinical question being asked. Selecting the most suitable modality can improve staging accuracy while limiting unnecessary radiation and cost.
Further reading
For broader context on imaging and treatment across tumor types, explore the Cancer section.
Source note: This article includes information reported by AuntMinnieEurope.



